Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Defence Therapeutics Inc (DTCFF)

Defence Therapeutics Inc (DTCFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade DTCFF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8584 +2.11%
on 04/25/24
1.2500 -29.88%
on 03/28/24
-0.3235 (-26.96%)
since 03/22/24
3-Month
0.8584 +2.11%
on 04/25/24
1.7380 -49.57%
on 01/30/24
-0.5235 (-37.39%)
since 01/25/24
52-Week
0.8584 +2.11%
on 04/25/24
3.1900 -72.52%
on 07/05/23
-1.9085 (-68.53%)
since 04/20/23

Most Recent Stories

More News
Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.8765 (-3.14%)
DTC.CN : 1.2200 (-2.40%)
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth

Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.8765 (-3.14%)
DTC.CN : 1.2200 (-2.40%)
Defence Therapeutics Announces Warrant Terms Amendment

Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies...

DTCFF : 0.8765 (-3.14%)
DTC.CN : 1.2200 (-2.40%)
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biotechnology company developing...

DTCFF : 0.8765 (-3.14%)
DTC.CN : 1.2200 (-2.40%)
Defence Completes 2nd Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 0.8765 (-3.14%)
DTC.CN : 1.2200 (-2.40%)
Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology

Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.8765 (-3.14%)
DTC.CN : 1.2200 (-2.40%)
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update

Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 0.8765 (-3.14%)
DTC.CN : 1.2200 (-2.40%)
Defence Therapeutics Completes 1st Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 0.8765 (-3.14%)
DTC.CN : 1.2200 (-2.40%)
Defence Financing

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 0.8765 (-3.14%)
DTC.CN : 1.2200 (-2.40%)
Defence Begins Trading on the OTCQB and Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 0.8765 (-3.14%)
DTC.CN : 1.2200 (-2.40%)

Key Turning Points

3rd Resistance Point 0.9398
2nd Resistance Point 0.9199
1st Resistance Point 0.8982
Last Price 0.8765
1st Support Level 0.8566
2nd Support Level 0.8367
3rd Support Level 0.8150

See More

52-Week High 3.1900
Fibonacci 61.8% 2.2993
Fibonacci 50% 2.0242
Fibonacci 38.2% 1.7491
Last Price 0.8765
52-Week Low 0.8584

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar